BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today filed its interim financial statements and management’s discussion and analysis for the second quarter ended December 31, 2007. All amounts are Canadian dollars unless otherwise noted.
